MindMaze

Switzerland-based MindMaze offers digital therapies for brain repair and neurorehabilitation for conditions such as Parkinson’s and Alzheimer’s disease. Its brain repair therapies include immersive activities through an animated gaming experience called MindPod Dolphin to assist the recovery of motor skills and cognitive decline. Gamified VR-based digital therapies MindMotion Pro (MMP) and MindMotion Go (MMG) assist with neurorehabilitation and received FDA clearance in 2017 and 2018, respectively. The solutions use a combination of wearable head-mounted displays and 3D motion capture cameras. MMP, which focuses on acute neurorehabilitation, maps a patient's movement onto 3D avatars and allows them to engage in VR-based interactive exercises designed to help stroke patients remain engaged in therapy.

These mapping capabilities were acquired in June 2017, when MindMaze bought motion analytics developer GaitUp. The platform also offers real-time multisensory feedback that allows therapists to adjust therapy on the fly. MMG is a portable neurotechnology device that uses VR to continue therapy for post-acute neurorehabilitation.

Other non-XR products and services offered include 1) Intento PRO, a device for treating individuals suffering from stroke impairments, 2) TOAP Run, a videogame to aid movement for individuals suffering from Parkinson’s disease, 3) the Physilog platform, which uses motion analytics to capture biomechanical data such as gait and balance, and 4) Brain Vitals, an FDA-approved assessment tool to measure changes in an individual’s cognitive functioning.

As of January 2024, MindMaze operated in 19 markets across North America and Europe and had delivered over 100,000 sessions. The company generates revenue by licensing its products to businesses and consumers that require virtual reality-optimized products.

Key customers and partnerships

Notable customers included the F1 team Alfa Romeo. The company also partnered with McLaren Racing to develop 'MindDrive' a safety and performance training solution for F1 drivers, leveraging the company's ELVIRA headset, in March 2019.

Funding and financials

In its most recent funding round in February 2022, MindMaze raised USD 105 million in a funding round led by Concord Health Partners (Concord), with participation from AlbaCore Capital Group and Hambro Perks. The funding was allocated to support its international growth plans and R&D initiatives. As a result of the investment from Concord, MindMaze entered a partnership with the American Hospital Association (AHA), a healthcare industry trade group whose strategic fund Concord operates.

Competitors: None under coverage. (MindMaze utilizes a mixed reality headset to specifically measure physiological metrics.)